WI Harper Group 1 week ago
EdiGene Inc., a genetic editing biotechnology company backed by WI Harper Group, announced the successful completion of the Pre-B2 round of financing of RMB 81.5 million. This round of investment was jointly invested by IDG Capital and Lilly Asia Fund. They also announced the launch of a new R&D collaboration effort to develop allogeneic T cells in cancer therapy, in cooperation with a clinical-stage company dedicated to developing innovative T cell therapy. The specific terms and name of the partner company were not disclosed.
“Gene editing is a recent revolutionary breakthrough in the field of biotechnology and a key and hope for the treatment of many congenital diseases. We are pleased to be an early investor to witness the EdiGene’s professional and technical achievements, and will continue to support their breakthroughs in clinical development and their efforts towards globalization.” said Mr. Peter Liu, Chairman of WI Harper Group.
EdiGene is a biotechnology company specializing in genome editing technology, founded by Professor Wei Wensheng, an internationally renowned genome editor. The company is committed to using genome editing technology to develop new therapies for diseases that are difficult to cure with traditional therapies, as well as to provide more innovative solutions for new drug development. The EdiGene series of genetic editing therapies includes: beta thalassemia gene editing therapy, blood tumor gene editing therapy, etc. Its existing research product pipelines are developed in parallel with internationally renowned gene editing and treatment companies.
In 2016, EdiGene won the China Patent Excellence Award, the Beijing Science and Technology Award in 2018, and was listed as one of the top 10 technology-intensive start-ups in 2017 by the industry’s top journal Nature Biotechnology. Currently, EdiGene has subsidiaries in Beijing, Guangzhou, Boston, and the USA.
“Allogeneic T-cell therapy is expected to achieve ‘off-the-shelf’, as well as effective quality control and lower cost, with great potential in China and elsewhere. We have been building allogeneic CAR- T platform. This new research collaboration further demonstrates our determination to develop such treatments to help cancer patients who are in need of treatment.” said Dr. Wei Dong, CEO of EdiGene. “We are very happy to complete a new round of financing, thanks to IDG Capital and Lilly Asia Fund for their continued support. We look forward to working with them and other existing investors to continue the next phase of the exciting research and development pipeline.”
Mr. Peter Liu, Chairman of WI Harper Group, said: “Gene editing is a recent revolutionary breakthrough in the field of biotechnology and a key and hope for the treatment of many congenital diseases. We are pleased to be an early investor to witness the EdiGene’s professional and technical achievements, and will continue to support their breakthroughs in clinical development and their efforts towards globalization.”
Mr. Johnson Lin, Partner at WI Harper Group, said: “After the era of chemical and biopharmaceuticals for 50 years, we believe that gene therapy has truly opened a new door in the history of human medicine. Let us have the opportunity to cure many congenital diseases. We are honored to be able to explore this new field with leaders like EdiGene. “
About EdiGene
EdiGene, Inc. is an innovative biopharmaceutical company founded in 2015 with headquarters in Beijing and subsidiaries in Guangzhou, Cambridge, and the USA. Based on genome-editing treatment technology, the company aims to address the medical needs that patients need to meet, and strives to develop innovative medical programs to treat genetic diseases and cancers that are difficult to cure. At the same time, based on high-throughput genome editing and screening technology for drug development. Creative solutions.
Translated from: https://mp.weixin.qq.com/s/Wiz8W_uHo00sGhMir0ERYw
